EP Patent

EP3813784B1 — Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith

Assigned to University of Michigan System · Expires 2024-01-10 · 2y expired

What this patent protects

Patent listed against tazemetostat-hydrobromide.

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: EP3813784B1
Jurisdiction: EP
Classification: —
Expires: 2024-01-10
Drug substance claim: No
Drug product claim: No
Assignee: University of Michigan System
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.